
Shares of drugmaker Emergent BioSolutions EBS.N rise ~2.9% to $9.68 premarket
Emergent says it gained exclusive commercial rights to Hikma Pharmaceuticals' HIK.L opioid reversal nasal spray, Kloxxado
Kloxxado rapidly reverses or blocks the effects of opioids, restoring normal respiration, especially when given within minutes of the first signs of an overdose
Under the terms of the agreement, Hikma will continue to manufacture the nasal spray, while Emergent will handle distribution
Up to last close, EBS up more than four-fold in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))